Newer HCV Agents Mostly Cost-Effective

March 17, 2015 10:29 AM

2 0

Newer HCV Agents Mostly Cost-Effective

Treating hepatitis C (HCV) with recently approved direct-acting agents is cost-effective in many patients, according to two studies, but both cautioned that wide use of the agents could have a substantial impact on healthcare costs.

Researchers led by Niteesh Choudhry, MD, PhD, of Brigham and Women's Hospital in Boston noted that demand for the agents is likely to be high and that, combined with their "very high prices, could substantially increase short-term overall drug spending for many public and private payers.

Read more

To category page